L-carbocisteine can cause cholestasis with vanishing bile duct syndrome in children: A case report

Abstract

Rationale: Vanishing bile duct syndrome (VBDS) is the acquired progressive destruction and disappearance of intrahepatic interlobular bile ducts in the absence of underlying liver or biliary tract disease, causing chronic cholestasis. Infections, drugs, toxins, malignant diseases, and certain immunological processes are associated with the development of this syndrome. There have been no reports of children developing VBDS as a consequence of the administration of L-carbocisteine. Patient concerns: A 9-year-old Japanese girl presented with fever, jaundice, and skin rash. Laboratory investigations revealed elevated levels of serum transaminases, γ-glutamyltransferase, and bilirubin. Histopathological features were consistent with a diagnosis of VBDS. Drug-induced lymphocyte stimulation tests (DLST) were positive for L-carbocisteine. Diagnosis: VBDS caused by L-carbocisteine. Interventions: Ursodeoxycholic acid and discontinuation of L-carbocisteine. Outcomes: The patient responded to treatment based upon discontinuation of L-carbocisteine and administration of ursodeoxycholic acid. Her transaminase and bilirubin levels were normalized gradually. Lessons: Physicians should be aware of the fact that L-carbocisteine can cause cholestasis with VBDS in children.